Literature DB >> 2013846

Simultaneous pharmacokinetic modeling of a drug and two metabolites: application to albendazole in sheep.

P Galtier1, M Alvinerie, J L Steimer, P Francheteau, Y Plusquellec, G Houin.   

Abstract

Albendazole pharmacokinetic parameters were determined in lambs after iv, oral, and intraruminal single administrations. The parent drug and two metabolites, albendazole sulfoxide and albendazole sulfone, were simultaneously determined in whole blood, plasma, and urine using an HPLC method. The parent drug was only recovered in plasma when injected intravenously. For other routes, only the two metabolites were detectable; they were present in red blood cells and plasma at equal concentrations. The pharmacokinetic parameters were determined by using compartmental models which simultaneously described the two oxidative steps and the urinary excretion of the sulfoxide derivative. Dose-dependent pharmacokinetics was studied in the dose range 0.95-3.8 mg/kg. The results showed that clearance remained constant within the tested dose range since the area under the curve normalized to the dose was similar in the cases of sulfoxide and sulfone metabolites, whatever the route of administration. The drug appeared to be extensively metabolized in the body regardless of the route of administration. Sulfoxidation probably took place in liver, but other tissues seemed to be responsible for the formation of the sulfoxide which has been described as the major anthelmintic derivative of albendazole.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013846     DOI: 10.1002/jps.2600800103

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Some pharmacokinetic parameters of oxfendazole in sheep.

Authors:  A L Soraci; N Mestorino; J O Errecalde
Journal:  Vet Res Commun       Date:  1997-05       Impact factor: 2.459

2.  Pharmacokinetics of ricobendazole after its intravenous, intraruminal and subcutaneous administration in sheep.

Authors:  E A Formentini; N Mestorino; J O Errecalde
Journal:  Vet Res Commun       Date:  2005-10       Impact factor: 2.459

3.  Transplacental transport of netobimin metabolites in ewes.

Authors:  C Cristofol; A Carretero; M Fernandez; M Navarro; J Sautet; J Ruberte; M Arboix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

4.  Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.

Authors:  C Gokbulut; V Y Cirak; B Senlik
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

5.  Aspects of the pharmacokinetics of albendazole sulphoxide in sheep.

Authors:  A Goudah
Journal:  Vet Res Commun       Date:  2003-10       Impact factor: 2.459

6.  Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer.

Authors:  Farhad Ghasemi; Morgan Black; Frederick Vizeacoumar; Nicole Pinto; Kara M Ruicci; Carson Cao Son Huu Le; Matthew R Lowerison; Hon Sing Leong; John Yoo; Kevin Fung; Danielle MacNeil; David A Palma; Eric Winquist; Joe S Mymryk; Paul C Boutros; Alessandro Datti; John W Barrett; Anthony C Nichols
Journal:  Oncotarget       Date:  2017-04-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.